Prescribing a dipeptidyl peptidase-4 inhibitor in adults with type 2 diabetes and comorbidities

Trajenta animation updated index image

This animation has been commissioned and funded by Boehringer Ingelheim Limited and developed in partnership with Guidelines in Practice.

View Trajenta (linagliptin) adverse event reporting and prescribing information for:

PC-GB-105125 Date of preparation: October 2021

Content for healthcare professionals

Access to this content is restricted to UK-based doctors, nurses, and pharmacists

If you are a UK-based doctor, nurse, or pharmacist, you must sign in to your account or register (for free) if you do not already have one. 

Return to homepage